Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03842943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 2, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jun 1, 2024 to Jun 1, 2026
    • Study completion date: Jun 1, 2027 to Jun 1, 2028
    v5
  2. Primary completion date: Mar 1, 2022 to Jun 1, 2024
    • Study completion date: Mar 1, 2022 to Jun 1, 2027
    v4
  3. Primary completion date: Mar 1, 2021 to Mar 1, 2022
    • Study completion date: Mar 1, 2024 to Mar 1, 2022
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 1, 2019 to Jul 3, 2019
    • Study sites: 0 to 1
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
Trial Details
NCT Number NCT03842943
Lead Sponsor University of Louisville
Conditions
(from sponsor)		 Cutaneous Melanoma
Related terms Melanoma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov